AI
MYGN icon

Atom Investors’s Myriad Genetics MYGN Stock Holding History

Atom Investors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,129
Closed -$384K – 734
2025
Q3 		$384K Buy
53,129
+33,544
+171% +$199K 0.03% 402
2025
Q2 		$104K Buy
+19,585
New +$116K 0.01% 552
2020
Q4 		– Sell
-12,100
Closed -$158K – 506
2020
Q3 		$158K Buy
+12,100
New +$153K 0.02% 423
2019
Q3 		– Sell
-129,091
Closed -$3.59M – 378
2019
Q2 		$3.59M Buy
+129,091
New +$3.65M 0.23% 132

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atom Investors's MYGN Position: Q4 2025 in Review

Atom Investors sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 53,129 shares — an estimated $384K sold.

Atom Investors first reported a position in MYGN in Q2 2019 and held it in 4 quarters. The position peaked at $3.59M in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Atom Investors reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 53,129 Myriad Genetics shares in Q4 2025, an estimated $384K.
  • Atom Investors first reported a position in Myriad Genetics in Q2 2019 and held it in 4 quarters.
  • Atom Investors's Myriad Genetics position peaked at $3.59M in Q2 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.